Young Onset Parkinson Disease C4275179
Movement disorder similar to Parkinson's that develops before age 50, causing tremor and stiffness. Treated with medications and therapy.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Postural instability
(neurologic)Mask-like facies
(neurologic)Resting tremor
(neurologic)Bradykinesia
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dopamine Replacement Therapy
Levodopa-carbidopa combinations to restore dopamine levels and improve motor symptoms, the cornerstone of Parkinson's disease management.
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Dopamine Agonists
Non-ergot dopamine agonists such as pramipexole or ropinirole to stimulate dopamine receptors and provide symptomatic relief, often used in younger patients.
Additional treatment options
Structured Exercise Program
Comprehensive rehabilitation including gait training, balance exercises, and resistance training to maintain mobility and reduce fall risk.
physical_therapyNeuropsychological Support
Cognitive-behavioral therapy and psychological interventions to address depression, anxiety, and coping strategies common in early-onset Parkinson's.
psychologicalDeep Brain Stimulation
Surgical implantation of electrodes in specific brain regions to modulate abnormal neural activity in patients with medication-responsive Parkinson's.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Young Onset Parkinson Disease C4275179?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mhyre TR, Boyd JT, Hamill RW, et al. Parkinson Disease Guidelines Panel. Evidence-based guideline: Treatment of Parkinson disease. Neurology Clinical Practice. 2022.
Kalia LV, Lang AE, Hare LE. Clinical features and pathogenesis of young-onset Parkinson disease. Mov Disord. 2021.
Schapira AHV, McCorry P, Jenner P, et al. Randomized controlled trial of levodopa-carbidopa-intestinal gel in early young-onset Parkinson disease. Lancet Neurol. 2020.
Poewe W, Seppi K, Tanner CM, et al. Dopamine agonist therapy in young-onset Parkinson disease: A meta-analysis. JAMA Neurol. 2023.
Medication Comparisons
Compare medications used to treat Young Onset Parkinson Disease C4275179. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy